Advances in Inflammatory Bowel Diseases (AIBD) 2025 Annual Conference
Orlando, Florida, US 08 December 2025 - 10 December 2025
Mortality risk elevated in UC patients with CAD
Ulcerative colitis (UC) patients with active coronary artery disease (CAD) appear to be at greater risk of mortality than those with Crohn’s disease (CD), suggest the results of a study presented at AIBD 2025.
Mortality risk elevated in UC patients with CAD
a day ago
Long-term anti-TNF use works wonders in moderate to severe IBD
The use of antitumour necrosis factor (anti-TNF) agents for at least 60 months is not only safe but also effective in the treatment of moderate to severe inflammatory bowel disease (IBD), according to a study presented at AIBD 2025.
Long-term anti-TNF use works wonders in moderate to severe IBD
a day ago
Real-world study supports high-dose IV iron for IBD-associated anaemia
Real-world evidence shows the efficacy and safety of high-dose intravenous (IV) iron for the treatment of anaemia in individuals with inflammatory bowel disease (IBD), irrespective of inflammatory activity.
Real-world study supports high-dose IV iron for IBD-associated anaemia
05 Jan 2026
Obefazimod hits targets in identical trials on active UC
Two phase III induction trials have demonstrated the efficacy and safety of obefazimod, an oral, first-in-class, small molecule, for the treatment of adults with moderate-to-severe ulcerative colitis (UC).
